Filing Details
- Accession Number:
- 0001209191-18-016866
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-05 18:39:40
- Reporting Period:
- 2018-03-01
- Accepted Time:
- 2018-03-05 18:39:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1001233 | Sangamo Therapeutics Inc | SGMO | Biological Products, (No Disgnostic Substances) (2836) | 680359556 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1691262 | Iii A. Curt Herberts | C/O Sangamo Therapeutics, Inc. Point Richmond Tech Ctr, 501 Canal Blvd. Richmond CA 94804 | Sr.vp & Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-03-01 | 171 | $12.12 | 14,796 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2018-03-01 | 1,430 | $9.41 | 16,226 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2018-03-01 | 8,087 | $14.07 | 24,313 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2018-03-01 | 5,312 | $3.50 | 29,625 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-01 | 15,000 | $23.06 | 14,625 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-01 | 171 | $0.00 | 171 | $12.12 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-01 | 8,087 | $0.00 | 8,087 | $14.07 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-01 | 1,430 | $0.00 | 1,430 | $9.41 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-01 | 5,312 | $0.00 | 5,312 | $3.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2023-12-11 | No | 4 | M | Direct | |
| 11,913 | 2024-12-10 | No | 4 | M | Direct | |
| 17,320 | 2025-12-07 | No | 4 | M | Direct | |
| 54,688 | 2027-01-25 | No | 4 | M | Direct |
Footnotes
- All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
- The price reported is a weighted average price. The shares were sold at prices ranging from $22.60 to $23.60 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Includes (a) 8,375 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date; and (b) 6,250 shares subject to restricted stock units granted on December 8, 2015 that will vest on December 8, 2018, subject to the Reporting Person's continued service with the Issuer through such date.
- Fully vested and exercisable.
- One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 11, 2014 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
- One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
- The stock option vested and became exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the January 26, 2017 grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter.
Billionaire Hedge Funds
